Chiococca alba (L.) Hitchc.: A Comprehensive Reference
1. Identity and Botanical Classification
Accepted Name and Synonyms
Chiococca alba (L.) Hitchc. is a species of flowering plant in the coffee family (Rubiaceae), native to Florida and the extreme southern tip of Texas in the United States, Bermuda, Mexico, Central America, the Caribbean, the Galápagos, and tropical South America. Accepted botanical synonyms include Lonicera alba L., Chiococca racemosa Jacq., and Chiococca brachiata Ruiz & Pav. Lonicera alba was described in 1753 by Carl Linnaeus; it was moved to the genus Chiococca in 1893 by A. S. Hitchcock, and is considered the type species of that genus.
The genus name Chiococca is derived from the Greek words chion (snow) and kokkos (berry), referring to the plant's distinctive white, snow-like fruits. The specific epithet alba is Latin for "white," alluding to the color of the drupes.
Common Names
Common names in English include David's milkberry, West Indian milkberry, cahinca, and West Indian snowberry. It is also known as West Indian milkberry, snow-berry, David's root, bejuco de berac, buenda, and liane des sorciers, and in Brazil as cainca, cipó-cruz, raiz-de-frade, and cruzeirinha. Other Brazilian vernacular names include cipó-cruzeiro cainca, cainana, caninana, purga-preta, raiz-preta, raiz-fedorenta, and dambre.
Morphological Description
West Indian milkberry is an evergreen woody vine or scrambling shrub that often grows on other vegetation and may reach a height of 6 m (20 ft). The opposite, simple leaves are 5–11 cm (2.0–4.3 in) long and may be elliptic to ovate or broadly lanceolate in shape. Yellow, bell-shaped flowers up to 1 cm (0.39 in) in length appear throughout the year on racemes or panicles of six to eight. The fruit is a white drupe 4–7 mm (0.16–0.28 in) in diameter that generally contains two dark brown seeds.
Plant Part Used and Common Preparations
In Brazilian traditional medicine, C. alba is used to treat a wide variety of ailments. Its roots are used as a diuretic, antiviral, anti-inflammatory, and as a treatment for rheumatism, hysteria, and snakebites. Although the use of the leaves is less frequent, leaves have been used to treat asthma, headaches, and diarrhea. The root as found in commerce is in small round pieces of different sizes and lengths, flexuous, with longitudinal rugae, brownish-black or grayish-brown, having its thin, cortical portion of a reddish-brown color, fragile, of a disagreeable odor, and a coffee-like taste succeeded by a pungent nauseousness. The bark is the medicinal part, and yields its properties to water or alcohol.
2. Traditional and Historical Use
Brazilian and South American Folk Medicine
The decoction and infusions of roots and other parts of Chiococca alba, alone or mixed with other plant species, have long been used in folk medicine as emetic, purgative, diuretic, antidiarrheic, antipyretic, tonic, and aphrodisiac, as well as for a variety of other purposes, such as to treat rheumatism, snakebites, flatulence, delayed menstruation, dementia, alcoholism, nervousness, and kidney troubles. A decoction of the whole plant was also reported to be effective as a laxative and as a remedy for gonorrhea, skin infections, and rheumatism.
In Brazil, the root is known as raiz pretta (black root). Besides cahincic acid (C₄₀H₆₄O₁₈), the root-bark contains, according to Pelletier, gummy, oily, and coloring matters. Its most important medicinal constituent historically recognized was the cahincic acid, or cahincin.
Mesoamerican and Caribbean Use
The C. alba was used for medicinal purposes by the Yucatec Maya traditional healers of southern Belize, in Central America, to treat fever, cold, and muscle pains. Root infusion is used in traditional medicine as antirheumatic, antiasthmatic, diuretic, anti-inflammatory, and for antimicrobial purposes. Chiococca alba occurs on all island groupings in the Lucayan Archipelago as well as the southern United States, the Caribbean region, and Central and South America. It is used in the Lucayan Archipelago for general strengthening teas, and to treat bed wetting and tuberculosis.
Pharmacopeial History in Europe and the Americas
It is of note that at least until the first half of the 20th century, Chiococca alba was listed in the Brazilian pharmacopeia as well as in those of several European countries. During the 19th and early 20th centuries, Chiococca alba roots were commercially available in Europe and the United States under the name "cahinca" or "cainca," imported primarily from South America for similar therapeutic purposes, including as a purgative and remedy for edema and syphilis. The plant was sold commercially in Europe and the United States for those purposes at one time.
A 19th-century medical account noted the "medicinal powers of the Cainca" in European journals. Baron Langdorf, Russian consul-general at Rio de Janeiro, first announced the remarkable virtues of this plant in Europe. It is the Chiococca racemosa of Linnaeus, of the natural family Rubiaceae, and is very abundant in the Antilles, the Floridas, and many parts of Brazil.
3. Phytochemistry: Key Constituents and Active Compounds
Terpenoids
A large number of plant specialized metabolites have been isolated from C. alba, including lignans, coumarins, ketoalcohols, triterpenes, iridoids, quinoline alkaloids, flavonoids, and saponins. Chiococca alba is also a rich source of diterpenes, including merilactone and ribenone. Merilactone is a structurally unique C₁₉ nor-diterpene found only in C. alba. Ribenone has an unusual heteroatom-containing ring with demonstrated activity against Leishmania and potential anticancer activity. C. alba also makes a number of kaurene-type diterpenes like 1-hydroxy-18-nor-kaur-4,16-dien-3-one; 15-hydroxy-kaur-16-en-3-one; kaur-16-en-19-ol; kaurenoic acid; ent-17-hydroxy-16α-kauran-3-one; and merilactone.
Two new ent-kaurane diterpenes, 1-hydroxy-18-nor-kaur-4,16-dien-3-one and 15-hydroxy-kaur-16-en-3-one, along with four known metabolites — kaur-16-en-19-ol, kaurenoic acid, merilactone, and ribenone — and a mixture of stigmasterol and β-sitosterol were isolated from the ethanolic root extract of Chiococca alba.
Triterpenoidal Saponins
Five triterpenoidal saponins were isolated from the roots of Chiococca alba (L.) Hitchc. (Rubiaceae). Two of these saponins, chiococcasaponin III and chiococcasaponin IV, were identified as new, and their structures were elucidated on the basis of NMR techniques and high-resolution electrospray mass spectrometry together with acid hydrolysis product analysis. The saponins of Chiococca alba are triterpene bidesmosides that contain glycidic moieties attached to the C-3 and C-28 carbon of their aglycone. The representative triterpene saponin chiococcasaponin IV has been characterized in genome-level chemical diversity studies as a key metabolite. Other terpenoids include the seco-iridoid glucoside Alboside I and diterpene kaurane-type ent-kaurenoic acid.
Alkaloids
Two biologically active quinoline alkaloids (El-Abadi et al., 1989), an oleanane-type triterpene, an ent-kaurane, an iridoid and a seco-iridoid, and a nor-seco-pimarane known as merilactone have been isolated from Chiococca alba roots, while lignans, coumarins, and two new keto alcohols have been found in the leaves.
Flavonoids
Chromatographic analysis of C. alba revealed 18 compounds, including rutin, naringin, myricetin, morin, and quercetin. The antiviral activity found in C. alba extracts can likely be attributed to the presence of major components, such as flavonoids.
Fatty Acids and Other Constituents
A preliminary analysis of the ethanolic extract's chemical composition by GC-MS revealed the presence of linear chain fatty acids — hexadecanoic, octadecanoic, eicosanoic, docosanoic, and tetracosanoic acids — with hexadecanoic acid (palmitic acid) as the predominant fatty acid in the mixture, as well as the triterpenoid constituent ursolic acid. Additional major components identified include 3,5-methoxycinnamic acid (5.49%), coniferol (2.98%), 1-(2-hydroxyphenyl)ethanone (2.61%), tetradecanoic acid (1.81%), and 1,6-anhydro-beta-D-glucopyranose (3.56%).
Historically Identified Constituent: Cahincic Acid
Cahincic acid (historically designated C₄₀H₆₄O₁₈) is white, without odor, of a taste at first scarcely perceptible but afterwards extremely bitter and slightly astringent. It is slightly soluble in water but readily soluble in alcohol, permanent in the air, and unaltered at 100°C. It reddens vegetable blues and unites with the alkalies but does not form crystallizable salts. It is thought to exist in the root as calcium subcahinate. When treated with diluted hydrochloric acid it is decomposed into glucose and other products, including chiococcaic acid (thought by some to be identical with quinovic acid), and later caincetin. Note: Cahincic acid as described in older texts corresponds in modern classification to triterpene saponins or glycosides isolated from the root bark.
4. Genomics and Biosynthetic Pathway Research
Chiococca alba (snowberry), a member of the Rubiaceae, has been used as a folk remedy for a range of health issues including inflammation and rheumatism, and produces a wealth of specialized metabolites including terpenes, alkaloids, and flavonoids. Researchers have generated a 558 Mb draft genome assembly for snowberry, which encodes 28,707 high-confidence genes.
A total of 27 putative terpene synthase genes were identified, including 10 that encode diterpene synthases. Functional validation of a subset of putative terpene synthases revealed that combinations of diterpene synthases yielded access to products of both general and specialized metabolism. Specifically, plausible intermediates in the biosynthesis of merilactone and ribenone — structurally unique antimicrobial diterpene natural products — were identified. Access to the C. alba genome will enable additional characterization of biosynthetic pathways responsible for health-promoting compounds in this medicinal species.
5. Scientific Evidence by Area of Use
5.1 Anti-Inflammatory Activity
Studies on the pharmacological properties of Chiococca alba and its constituents have revealed anti-inflammatory effects (Schapoval et al., 1983), antimicrobial action against Staphylococcus aureus (Borges-Argáez et al., 1997), as well as anticancer activity (Carbonezi et al., 1997).
As part of investigations on the chemical profile and pharmacological activity of the roots of C. alba, researchers evaluated the activity of saponin fractions against in vitro lipopolysaccharide-induced inflammation. The leaf and root of Chiococca alba were the subject of use reports for external application; the latter may be attributable to the anti-inflammatory effects of saponins in the roots.
Evidence strength: Anti-inflammatory activity has been demonstrated at the in vitro and early preclinical level; no human clinical trials evaluating anti-inflammatory endpoints have been published based on available sources.
5.2 Antimicrobial Activity
A newly isolated ent-kaurane (ent-17-hydroxy-16α-kauran-3-one) from the roots showed weak antimicrobial activity when tested against Staphylococcus aureus. Merilactone and ribenone were identified as structurally unique antimicrobial diterpene natural products.
Evidence strength: Antimicrobial evidence derives from in vitro bioassays and phytochemical isolation studies, with activity described as weak to moderate for individual isolated compounds. No human clinical data are available.
5.3 Antiviral Activity
A 2024 study examined C. alba, a Neotropical plant traditionally used by Yucatec Maya healers as an antipyretic and antirheumatic, as a potential source of antiviral agents. The study aimed to evaluate the antiviral potential of C. alba methanolic extracts (CAH21 and CAH24) against Chikungunya virus (CHIKV) and Mayaro virus (MAYV) through preliminary in vitro and in silico analyses. The cytotoxicity of two methanolic extracts from C. alba roots was assessed in Vero cells using the neutral red assay, and viral activity was determined via plaque assay post-treatment.
Given the observed antiviral effects, the researchers used computational predictions to explore interactions between the multifunctional nsP2 proteases and secondary metabolites identified in C. alba extracts. The metabolites were identified using HPLC and GC-MS. Phytochemical analysis revealed the presence of flavonoids, coumarins, and phenolic acids in the C. alba extracts.
Evidence strength: The 2024 antiviral study represents preliminary in vitro and in silico evidence only. No human clinical antiviral trials have been reported. The findings are hypothesis-generating and require further validation.
5.4 Immunomodulatory and Adjuvant Activity (Leishmaniasis Research)
The saponins of Chiococca alba are triterpene bidesmosides that contain glycidic moieties attached to the C-3 and C-28 carbon of their aglycone. Their adjuvant potential increases in direct relationship to the length and hydrophilicity of the C-28 attached sugar chain. The sugar chains contain: arabinose-rhamnose in the CA2, arabinose-rhamnose-xylose in the CA3X, arabinose-rhamnose-apiose in the CA3, and arabinose-rhamnose-apiose-apiose in the CA4 saponin.
All saponins were formulated with the FML antigen for mice prophylaxis against visceral leishmaniasis. The immune response was studied using ELISA-antibody assay, monitoring of intradermal response to Leishmania antigens, cytokine expression in supernatants, and intracellular staining of in vitro cultured splenocytes. After challenge, significant increases of IgG and IgG2a antibodies were noted only in the CA4-vaccinated mice, which showed extended IDR, higher IFN-γ production by CD8+ and TNF-α production by CD4+ T cells, higher TNF-α secretion, and the highest reduction of parasite load (78%).
The increases in IDR, CD4-TNF-α, CD8-IFN-γ, and CD8-TNF-α by the CA4 vaccine were strong correlates of protection and were significantly correlated to the decrease of parasite load (p = −0.007). Protection generated by the CA4 vaccine was mainly mediated by a CD4+ T cell and a TNF-α-driven response, with a lower contribution of CD8+ T cells, as confirmed by an in vivo depletion with monoclonal antibodies and by vaccination assays in TNF-α-receptor knock-out mice.
Evidence strength: These are preclinical murine studies. Results are scientifically notable as the CA4 saponin demonstrated strong adjuvant properties in an animal model of visceral leishmaniasis, but no human clinical trials have been conducted using C. alba saponins as vaccine adjuvants.
5.5 Larvicidal and Mosquito-Repellent Activity
The methanolic extracts of C. alba showed larvicidal activity (LC₅₀ = 82 [72–94] mg/mL) without killing or affecting the predatory abilities of Belostoma anurum on mosquito larvae. In silico predictions revealed the molecular interactions between rutin and the AeagOBP1 receptor as one possible mechanism for the repellent potential recorded for formulations containing C. alba extracts. Low cytotoxicity against mammalian cell lines reinforces the selectivity of C. alba extracts. These findings highlight the potential of C. alba and one of its constituents (rutin) as alternative tools to be integrated into the management of Aedes aegypti mosquitoes.
Evidence strength: Preliminary laboratory and in silico data only; no field or human studies on repellent/larvicidal effects have been conducted.
5.6 Gastrointestinal Effects (Purgative, Diuretic, Emetic, Antidiarrheal)
The roots have several uses in herbal medicine, including as a laxative, diuretic, emetic, and antidiarrheal. These uses are among the most extensively documented in ethnobotanical literature across multiple cultures. However, based on available sources, formal clinical trials assessing these traditional gastrointestinal indications have not been published in the peer-reviewed scientific literature; the evidence base remains ethnobotanical and historical.
6. Body Systems and Health Areas Associated with Chiococca alba
- Musculoskeletal system: Used as a folk remedy for inflammation and rheumatism.
- Urinary system: Traditionally used as a diuretic and for kidney troubles.
- Digestive system: Used as emetic, purgative, antidiarrheic, and for flatulence.
- Immune/infectious disease: Roots are used as antiviral, anti-inflammatory, and for snakebite treatment.
- Respiratory system: Leaves have been used to treat asthma and headaches.
- Reproductive/gynecological system: Historically used for delayed menstruation and as an aphrodisiac.
- Skin/integumentary system: Whole-plant decoctions reported as remedy for skin infections.
- Neurological/psychological: Traditional use for nervousness, dementia, and alcoholism is documented in historical Brazilian sources.
7. Dosage Forms and Reported Dosages
The roots of Chiococca alba have been utilized in traditional folk medicine across the Caribbean and Latin America for digestive disorders, urinary tract issues, and other ailments. Preparations typically involve decoctions or infusions of the root bark, administered orally.
In the scientific toxicology literature, specific dosages used in preclinical studies are reported as follows:
- Single oral doses of ethanolic extract (EE) caused hypoactivity, but no deaths were noted up to the highest dose tested (2,000 mg/kg) in mice.
- EE at 500 mg/kg p.o. reduced mouse locomotion in the open field test.
- EE was markedly more toxic when given by intraperitoneal (i.p.) and subcutaneous (s.c.) routes. Acute approximate lethal doses (ALD) were 125 mg/kg (males) and 250 mg/kg (females) by i.p. route, and 250 mg/kg (both sexes) by s.c. route.
- Repeated administration of EE by gavage for 14 days caused no deaths.
In the larvicidal study, the methanolic extract showed larvicidal activity at an LC₅₀ of 82 (72–94) mg/mL.
No standardized therapeutic dosage for human consumption has been established in any pharmacopeia currently in use, and no clinical trial dose-ranging data in humans is available in the peer-reviewed literature identified by this review.
8. Safety Considerations
Toxicological Profile (Preclinical)
A formal study was undertaken to evaluate the toxicological properties of an ethanolic extract from Chiococca alba roots (EE), including mutagenicity in the Salmonella assay and acute and subacute toxicity to mice. Single oral doses of EE caused hypoactivity, but no deaths were noted up to the highest dose tested (2,000 mg/kg).
EE was markedly more toxic when given by intraperitoneal and subcutaneous routes. Acute approximate lethal doses were 125 mg/kg (males) and 250 mg/kg (females) by i.p. route, and 250 mg/kg (both sexes) by s.c. route, respectively. Deaths after single doses were preceded by hypoactivity, ataxia, and lethargy.
Notwithstanding the widespread medicinal use of Chiococca alba root extracts in Brazil and elsewhere, as of the publication of the 2006 toxicological study, there was no prior published study on their toxicological properties. Tradition in use, by no means, warrants that a medicinal plant is safe, particularly with regard to mutagenicity and carcinogenicity, because cause–effect relationships in these areas are rather complex and not easily recognized by the population.
Route-Dependent Toxicity
The toxicology study established a critical distinction in C. alba extract safety: while single oral doses caused hypoactivity but no mortality up to 2,000 mg/kg, the extract was markedly more toxic when administered by intraperitoneal and subcutaneous routes. This suggests that oral ingestion and parenteral administration carry substantially different risk profiles. The clinical relevance of these findings to oral folk use preparations is difficult to directly extrapolate due to differences in bioavailability and route of administration.
Traditional Preparation Warning
The root has historically been used, among other purposes, as an emetic and purgative — properties that themselves carry risk of harm, particularly from dehydration and electrolyte disturbance, if preparations are used in high doses. The root is described as a drastic purgative in botanical literature.
Absence of Human Safety Data
No controlled human clinical trials, systematic reviews, or formal pharmacovigilance studies assessing the safety of Chiococca alba preparations in humans were identified in the peer-reviewed literature available at the time of this review. Identification of the biologically active constituents in C. alba extracts would be necessary to allow the active principle to be used without interference from other metabolites. There is no current monograph from WHO, ESCOP, the German Commission E, or the EMA specifically evaluating Chiococca alba as a medicinal ingredient.
References
Go back